| CAS NO: | 198474-05-4 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 198474-05-4 |
| 别名 | 3-(5-氟-1H-吲哚-3-基)-2,5-吡咯烷二酮,EOS200271 |
| Canonical SMILES | O=C(C(C1=CNC2=C1C=C(F)C=C2)C3)NC3=O |
| 分子式 | C12H9FN2O2 |
| 分子量 | 232.21 |
| 溶解度 | DMSO : ≥ 28 mg/mL (120.58 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor. PF-06840003 reverses IDO-1-induced T-cell anergy in vitro[1]. PF-06840003 reduces intratumoral kynurenine levels in mice by >80% and inhibits tumor growth in multiple preclinical syngeneic models in mice, in combination with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours[1]. [1]. Tumang J, et al. PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr4863. |
m.cnreagent.com